TRDA – entrada therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Pompe Disease Pipeline Insight 2024,with Comprehensive Insights for 15+ Companies and 20+ Pipeline Drugs in the Pompe Disease Pipeline Landscape [Yahoo! Finance]
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $25.00 to $28.00. They now have an "outperform" rating on the stock.
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at HC Wainwright from $18.00 to $20.00. They now have a "buy" rating on the stock.
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Form SC 13G/A Entrada Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form 4 Entrada Therapeutics, For: Nov 11 Filed by: Sethuraman Natarajan
Form 4 Entrada Therapeutics, For: Nov 11 Filed by: WENTWORTH KORY JAMES
Form 144 Entrada Therapeutics, Filed by: WENTWORTH KORY JAMES
Form 144 Entrada Therapeutics, Filed by: Sethuraman Natarajan
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.